TP53 and cancer: MDM2 SNP309 has been shown to modify this cancer risk in multiple cohorts of TP53 mutation carriers in an age- and gender-dependent manner.22–26 Importantly, genetically engineered mouse models carrying either alleles of MDM2 SNP309 and a highly penetrant LFS p53 mutation demonstrated similar allele-specific differences in age-dependent cancer incidence.26 Together, observations such as these suggest that SNPs could potentially modify ACC cancer risk.